Novavax (NVAX) Misses Q2 EPS by 4c

Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $8.03 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes